Tomas J. Heyman's most recent trade in Akero Therapeutics Inc was a trade of 9,398 Common Stock done . Disclosure was reported to the exchange on June 3, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Akero Therapeutics Inc | Tomas J. Heyman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jun 2025 | 9,398 | 9,398 (0%) | 0% | 0 | Common Stock | |
| Exelixis Inc | Tomas J. Heyman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 May 2025 | 9,812 | 42,282 (0%) | 0% | 0 | Common Stock | |
| OptiNose Inc | Tomas J. Heyman | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 21 May 2025 | 5,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Exelixis Inc | Tomas J. Heyman | Director | Sale of securities on an exchange or to another person at price $ 44.29 per share. | 21 May 2025 | 4,544 | 32,470 (0%) | 0% | 44.3 | 201,254 | Common Stock |
| OptiNose Inc | Tomas J. Heyman | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 21 May 2025 | 3,566 | 0 | - | - | Stock Option (Right to Buy) | |
| OptiNose Inc | Tomas J. Heyman | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 21 May 2025 | 2,133 | 0 | - | - | Stock Option (Right to Buy) | |
| OptiNose Inc | Tomas J. Heyman | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 21 May 2025 | 1,925 | 0 | - | - | Stock Option (Right to Buy) | |
| OptiNose Inc | Tomas J. Heyman | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 21 May 2025 | 962 | 0 | - | - | Stock Option (Right to Buy) | |
| Akero Therapeutics Inc | Tomas J. Heyman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2024 | 26,000 | 26,000 | - | - | Stock Option (Right to Buy) | |
| OptiNose Inc | Tomas J. Heyman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jun 2024 | 75,000 | 75,000 | - | - | Stock Option (Right to Buy) | |
| Exelixis Inc | Tomas J. Heyman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 May 2024 | 18,838 | 37,014 (0%) | 0% | 0 | Common Stock | |
| Akero Therapeutics Inc | Tomas J. Heyman | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Jun 2023 | 26,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Akero Therapeutics Inc | Tomas J. Heyman | Director | Sale of securities on an exchange or to another person at price $ 54.67 per share. | 16 Jun 2023 | 26,000 | 0 (0%) | 0% | 54.7 | 1,421,529 | Common Stock |
| Akero Therapeutics Inc | Tomas J. Heyman | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 25.04 per share. | 16 Jun 2023 | 26,000 | 26,000 (0%) | 0% | 25.0 | 651,040 | Common Stock |
| Xilio Therapeutics Inc | Tomas J. Heyman | Director | 12 Jun 2023 | 13,200 | 13,200 | - | - | Stock Option (right to buy) | ||
| OptiNose Inc | Tomas J. Heyman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2023 | 53,500 | 53,500 | - | - | Stock Option (Right to Buy) | |
| Invivyd Inc | Tomas J. Heyman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 May 2023 | 50,000 | 50,000 | - | - | Stock Option (Right to Buy) | |
| Xilio Therapeutics Inc | Tomas J. Heyman | Director | 15 Sep 2022 | 26,400 | 26,400 | - | - | Stock Option (right to buy) | ||
| Invivyd Inc | Tomas J. Heyman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Jun 2022 | 75,000 | 75,000 | - | - | Stock Option (Right to Buy) | |
| OptiNose Inc | Tomas J. Heyman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2022 | 32,000 | 32,000 | - | - | Stock Option (Right to Buy) | |
| Akero Therapeutics Inc | Tomas J. Heyman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jun 2022 | 15,000 | 15,000 | - | - | Stock Option (Right to Buy) | |
| OptiNose Inc | Tomas J. Heyman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2021 | 14,439 | 14,439 | - | - | Stock Option (Right to Buy) | |
| Akero Therapeutics Inc | Tomas J. Heyman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jun 2021 | 13,000 | 13,000 | - | - | Stock Option (Right to Buy) | |
| OptiNose Inc | Tomas J. Heyman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Dec 2020 | 28,879 | 28,879 | - | - | Stock Option (Right to Buy) |